BR0016992A - Processos para o preparo de polimorfos de claritromicina - Google Patents

Processos para o preparo de polimorfos de claritromicina

Info

Publication number
BR0016992A
BR0016992A BR0016992-7A BR0016992A BR0016992A BR 0016992 A BR0016992 A BR 0016992A BR 0016992 A BR0016992 A BR 0016992A BR 0016992 A BR0016992 A BR 0016992A
Authority
BR
Brazil
Prior art keywords
clarithromycin
processes
formula
preparation
polymorphs
Prior art date
Application number
BR0016992-7A
Other languages
English (en)
Inventor
Igor Lifshitz
Ilya Avrutov
Edi Schwartz
Basem Masarwa
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR0016992A publication Critical patent/BR0016992A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"PROCESSOS PARA O PREPARO DE POLIMORFOS DE CLARITROMICINA". A presente invenção refere-se a processos para converter claritromicina Fórmula I em claritromicina Fórmula II, que incluem o empaste da claritromicina Fórmula I em água. A presente invenção refere-se também a processos para o preparo de claritromicina Fórmula II por meio da conversão de eritromicina A em claritromicina e a subseq³ente conversão de claritromicina Fórmula I em claritromicina Fórmula II por empaste.
BR0016992-7A 2000-01-11 2000-12-15 Processos para o preparo de polimorfos de claritromicina BR0016992A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
PCT/US2000/033844 WO2001051059A1 (en) 2000-01-11 2000-12-15 Processes for preparing clarithromycin polymorphs

Publications (1)

Publication Number Publication Date
BR0016992A true BR0016992A (pt) 2002-12-31

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016992-7A BR0016992A (pt) 2000-01-11 2000-12-15 Processos para o preparo de polimorfos de claritromicina

Country Status (22)

Country Link
US (2) US6624292B2 (pt)
EP (1) EP1280535B1 (pt)
JP (1) JP2003519661A (pt)
KR (1) KR20020071012A (pt)
CN (1) CN1450903A (pt)
AT (1) ATE288758T1 (pt)
AU (2) AU2261901A (pt)
BR (1) BR0016992A (pt)
CA (1) CA2397092A1 (pt)
DE (1) DE60018119T2 (pt)
DK (1) DK1280535T3 (pt)
ES (1) ES2236023T3 (pt)
HR (1) HRP20020572A2 (pt)
HU (1) HUP0204252A3 (pt)
IL (1) IL150698A0 (pt)
IS (1) IS6463A (pt)
PL (1) PL356645A1 (pt)
PT (1) PT1280535E (pt)
RU (1) RU2002118308A (pt)
SI (1) SI1280535T1 (pt)
WO (1) WO2001051059A1 (pt)
ZA (1) ZA200205229B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU783055B2 (en) * 1999-12-16 2005-09-22 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
PT1280535E (pt) * 2000-01-11 2005-04-29 Teva Pharma Processos para a preparacao de polimorfos de claritromicina
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1313486A1 (en) * 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
MXPA02009587A (es) * 2000-03-28 2003-05-14 Biochemie Gmbh Particulas granuladas con sabor enmascarado.
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
ATE365557T1 (de) * 2001-08-13 2007-07-15 Fond Salvatore Maugeri Clinica Verwendung von clarithromycin zur herstellung eines medikaments für die behandlung von arthrosis deformans
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8758820B2 (en) 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007064595A2 (en) * 2005-11-29 2007-06-07 Bausch & Lomb Incorporated Fluocinolone acetonide drug substance polymorphic interconversion
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2011026234A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
TWI788702B (zh) 2013-11-15 2023-01-01 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
AU733646B2 (en) 1996-07-29 2001-05-17 Bgp Products Operations Gmbh Preparation of crystal form II of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
AU783055B2 (en) * 1999-12-16 2005-09-22 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
PT1280535E (pt) * 2000-01-11 2005-04-29 Teva Pharma Processos para a preparacao de polimorfos de claritromicina
EP1313486A1 (en) 2000-02-29 2003-05-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
SI1280535T1 (pt) 2005-08-31
ZA200205229B (en) 2003-06-30
AU2001222619C1 (en) 2006-01-12
JP2003519661A (ja) 2003-06-24
DE60018119T2 (de) 2006-05-04
PT1280535E (pt) 2005-04-29
IL150698A0 (en) 2003-02-12
AU2261901A (en) 2001-07-24
HRP20020572A2 (en) 2005-04-30
IS6463A (is) 2002-07-09
US6624292B2 (en) 2003-09-23
CA2397092A1 (en) 2001-07-19
EP1280535B1 (en) 2005-02-09
EP1280535A4 (en) 2003-02-05
CN1450903A (zh) 2003-10-22
US20020028920A1 (en) 2002-03-07
PL356645A1 (en) 2004-06-28
KR20020071012A (ko) 2002-09-11
DE60018119D1 (de) 2005-03-17
EP1280535A1 (en) 2003-02-05
US6987175B2 (en) 2006-01-17
HUP0204252A2 (hu) 2003-03-28
AU2001222619B8 (en) 2005-07-14
AU2001222619B2 (en) 2005-04-28
US20030216555A1 (en) 2003-11-20
DK1280535T3 (da) 2005-04-04
ES2236023T3 (es) 2005-07-16
ATE288758T1 (de) 2005-02-15
RU2002118308A (ru) 2004-02-20
WO2001051059A1 (en) 2001-07-19
HUP0204252A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
BR0016992A (pt) Processos para o preparo de polimorfos de claritromicina
TR199901874T2 (xx) 3'-n-oksit,3'-n-dimetilamin, 9-oksim eritromisin A t�revleri.
BR0110667A (pt) Processo para a preparação de um composto, e, composto
DE60108279D1 (de) Mischventil für Wasser
BR9910296A (pt) Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado
HK1062288A1 (en) Hydrogen generation from water split reaction
DK1149840T5 (da) Fremgangsmåde til fremstilling af drospirenon
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
ATE552985T1 (de) Abbildungssystem
BR0206372A (pt) Processo para sintetizar um composto
ES2190275T3 (es) Nuevos intermediarios y procedimiento para la preparacion de agentes antibioticos macrolidos a partir de dichos intermediarios.
SE9904044D0 (sv) Compounds
BRPI0417700A (pt) método para separação de metil mercaptano de misturas de gás de reação
DE10393044D2 (de) Fischsilberanaloge Perlglanzpigmente, hergestellt durch enzymatische Umsetzung
BR0002982A (pt) Processo para a preparação de reagentes de grignard e novos reagentes de grignard
BR9813897A (pt) Derivados de bifenila como farmacêuticos
BR9807726A (pt) Processo para a preparação de um composto
BR0116704A (pt) Antìgenos de streptococcus pyogenes e fragmentos de dna correspondentes
BR0112787B1 (pt) composiÇço de soluÇço topicamente administrÁvel.
BR9902525A (pt) Processo para compostos de ácido pirrolidinil-hidroxâmico
BR0312672A (pt) Processo para a preparação de compostos
ES2160085B1 (es) Dihidrato de eritromicina a oxima
DK1284983T3 (da) Fremgangsmåde til omdannelse af carbonylgruppen i stilling 4" i cladinosemotivet i et aza-makrolid til et aminderivat
Lee A Feasibility Study for Primary School Buildings for Open Education
BR7800577U (pt) Dispositivos para locomoção em canoas, barcos ultraleves e similares,

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]